Condition

Unresectable HER2-Positive Breast Carcinoma

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 2 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials2

Recruiting1

Common interventions18

Lead sponsors shown1

Clinical trials

2 shown

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast CancerNCT07137416 · 2026-10-05

RECRUITING

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast CancerNCT03199885 · 2019-04-05

TERMINATED

Common interventions

AtezolizumabDRUG1 BiopsyPROCEDURE1 Biopsy ProcedurePROCEDURE1 Biospecimen CollectionPROCEDURE1 Bone ScanPROCEDURE1 Computed TomographyPROCEDURE1 DocetaxelDRUG1 Echocardiography TestPROCEDURE1 Magnetic Resonance ImagingPROCEDURE1 Multigated Acquisition ScanPROCEDURE1 PaclitaxelDRUG1 PertuzumabBIOLOGICAL1 PidnarulexDRUG1 Placebo AdministrationOTHER1 Quality-of-Life AssessmentOTHER1 Radiologic Imaging ProcedurePROCEDURE1 TrastuzumabBIOLOGICAL1 Trastuzumab DeruxtecanBIOLOGICAL1

Leading sponsors

National Cancer Institute (NCI) 2

Trial status mix

RECRUITING1

TERMINATED1

Phase mix

PHASE11

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.